Johnson & Johnson $JNJ Stock: Cyndeo Wealth Partners LLC Lowers Position

Key Points

• Cyndeo Wealth Partners reduced its Johnson & Johnson position by 7.3% in the third quarter, selling 5,710 shares and retaining 72,577 shares valued at approximately $19.2 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly revenue of $25.4 billion and adjusted EPS of $2.59, exceeding analyst expectations, while revenue rose 5.9% year over year. The company set 2026 EPS guidance at $11.05–$11.15.
• The company declared a $1.34 quarterly dividend, equivalent to $5.36 annually and a 2.1% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $274.87, though MedTech weakness and JNJ’s premium valuation remain concerns.

Cyndeo Wealth Partners LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,577 shares of the company's stock after selling 5,710 shares during the period. Johnson & Johnson comprises about 0.8% of Cyndeo Wealth Partners LLC's holdings, making the stock its 29th largest holding. Cyndeo Wealth Partners LLC's holdings in Johnson & Johnson were worth $19,214,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Selective Wealth Management Inc. raised its holdings in shares of Johnson & Johnson by 44.5% during the 3rd quarter. Selective Wealth Management Inc. now owns 2,545 shares of the company's stock valued at $645,000 after buying an additional 784 shares in the last quarter. Aspiriant LLC boosted its stake in Johnson & Johnson by 1.4% in the third quarter. Aspiriant LLC now owns 20,259 shares of the company's stock worth $5,363,000 after buying an additional 278 shares in the last quarter. Perryman Financial Advisory Inc. AD boosted its stake in Johnson & Johnson by 1.6% in the third quarter. Perryman Financial Advisory Inc. AD now owns 48,974 shares of the company's stock worth $12,965,000 after buying an additional 782 shares in the last quarter. Pension & Wealth Management Advisors Inc. grew its position in Johnson & Johnson by 46.0% during the third quarter. Pension & Wealth Management Advisors Inc. now owns 3,020 shares of the company's stock valued at $800,000 after acquiring an additional 951 shares during the last quarter. Finally, Cornerstone Wealth Advisors Inc. grew its position in Johnson & Johnson by 9.3% during the third quarter. Cornerstone Wealth Advisors Inc. now owns 1,220 shares of the company's stock valued at $323,000 after acquiring an additional 104 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $255.54 on Friday. The stock's 50 day simple moving average is $265.66 and its 200 day simple moving average is $249.61. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The firm has a market cap of $615.82 billion, a price-to-earnings ratio of 38.72, a PEG ratio of 2.53 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. During the same period in the previous year, the firm earned $2.80 EPS. The business's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is presently 81.21%.

Wall Street Analyst Weigh In

Several research analysts have commented on JNJ shares. The Goldman Sachs Group reissued a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Scotiabank reaffirmed an "outperform" rating and issued a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating on the stock in a report on Thursday. Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. Finally, Argus set a $300.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $274.87.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last three months. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson?
• Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target.
• Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying
• Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss
• Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.